Multi-antigen-targeted T-cell therapy to treat patients with relapsed/refractory breast cancer

Abstract

MultiTAA T cells were well tolerated and induced disease stabilization in a patient with refractory BC. This was associated with <i>in vivo</i> T-cell expansion, persistence, and antigen spreading. Future directions of this approach may include additional strategies to enhance the therapeutic benefit of multiTAA T cells in patients with BC.